Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SDI-118
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : AbbVie Inc
Deal Size : $1,000.0 million
Deal Type : Acquisition
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
Details : AbbVie has beefed up its neuro pipeline by acquiring Belgium-based Syndesi Therapeutics. This acquisition gives AbbVie access to Syndesi’s lead candidate SDI-118, a small molecule that is under evaluation to treat Alzheimer’s disease and major depres...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $130.0 million
March 01, 2022
Lead Product(s) : SDI-118
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : AbbVie Inc
Deal Size : $1,000.0 million
Deal Type : Acquisition
Lead Product(s) : SDI-118
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : P1vital
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of SDI-118 in Participants in Remission From Depression
Details : SDI-118 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2022
Lead Product(s) : SDI-118
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : P1vital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SDI-118 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cognitive Dysfunction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 20, 2022
Reset All
